abstract

Temozolomide and irinotecan in adult patients with recurrent Ewing Sarcoma
Abstract ID : 1212
Submitted by : Stefano Ferrari the 2016-02-11 18:20:13
Category : Ewing Sarcoma
Typology : Communication orale / Oral communication
Status : Validated
Authorisation to disclose : Yes/Oui
------------------------------------Background: The activity of temozolomide (TEM) and irinotecan (IRI) in recurrent Ewing sarcoma has been shown in
retrospective studies mostly based on pediatric population. This joint study has focused on the use of TEMIRI in an adult
population of patients with recurrent Ewing sarcoma.
Methods: Three referral centers participated to to the study. Patients receiving TEM (100 mg/m2/day orally) and IRI (40
mg/m2/die IV), day 1 to 5, every 21 days, and with measurable disease were eligible. Daily oral cefixime was used to
reduce irinotecan-associated diarrhea
Overall response rate (ORR: CR + PR) and , 6-mo PFS were assessed.
Results: 38 patients (Male/Female ratio 2.2, median age 28 (18-65)).
ECOG 0: 21 (55%), ECOG ≥ 1: 17 (45%). 27 (71%) patients had received 2 or more chemotherapy lines for recurrent
disease. High dose chemotherapy (HDT) with PBSC support had been previously used in 10 patients. Multiple sites of
metastases were reported in 27 (71%) patients, 8 had only lung metastases and 3 bone lesion with soft tissue
component.
Median number of cycles was 5 (range: 1-33).
No toxic death was recorded, grade 3-4-chemotherapy toxicity was reported in 4 patients (2 hematological, 2
gastrointestinal toxicities).
ORR: 13 ( 34%) patients had measurable tumor response (CR 2, 11 PR). Stable disease was reported in 13 (34%)
patients, tumor progression was reported in 12 (32%) patients
6- month PFS rate was 44% without differences according to sex, number of lines of treatment, ECOG status, previous
treatment with HDT.
Conclusions: In adult patients with recurrent Ewing sarcoma TEMIRI is an active regimen with a good toxicity profile.
------------------------------------Keywords : Ewing Sarcoma Temozolomide Irinotecan
Authors :
References : , , ,
Authors
Ferrari Stefano 1, Jones Robin Lewis 2, Grignani Giovanni 3, Picci Piero 1, D'Ambrosio Lorenzo 3, Paioli Anna 1,
Cesari Marilena 1, Longhi Alessandra 1, Palmerini Emanuela 1,
1. Oncology, Istituto Ortopedico Rizzoli, Bologna, ITALY
2. Oncology, Royal Marsden Hospital, London, UNITED KINGDOM
3. Oncology, IRCCS Candiolo, Torino, ITALY
4. Oncology, istituto Ortopedico Rizzoli, Bologna, ITALY
Authors (raw format)
Stefano Ferrari - email : [email protected] Institution : Istituto Ortopedico Rizzoli Department : Oncology City :
Bologna Country : ITALY Speaker : Yes
Robin Lewis Jones - email : [email protected] Institution : Royal Marsden Hospital Department : Oncology City :
London Country : UNITED KINGDOM Speaker : No
Giovanni Grignani - email : [email protected] Institution : IRCCS Candiolo Department : Oncology City : Torino
Country : ITALY Speaker : No
Piero Picci - email : [email protected] Institution : Istituto Ortopedico Rizzoli Department : Oncology City : Bologna
Country : ITALY Speaker : No
Lorenzo D'Ambrosio - email : [email protected] Institution : IRCCS Candiolo Department : Oncology City :
Torino Country : ITALY Speaker : No
Anna Paioli - email : [email protected] Institution : Istituto Ortopedico Rizzoli Department : Oncology City : Bologna
Country : ITALY Speaker : No
Marilena Cesari - email : [email protected] Institution : Istituto Ortopedico Rizzoli Department : Oncology City :
Bologna Country : ITALY Speaker : No
Alessandra Longhi - email : [email protected] Institution : istituto Ortopedico Rizzoli Department : Oncology City :
Bologna Country : ITALY Speaker : No
Emanuela Palmerini - email : [email protected] Institution : istituto Ortopedico Rizzoli Department : Oncology
City : Bologna Country : ITALY Speaker : No